VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study

Robert Metcalf; S. Laban; C. A. Kristensen; T-E. Ciuleanu; I. Braña; A. Soria Rivas; S. M. Dieter; A. Bols; M. D. Forster; M. R. Covela; J. Christian; F. D. Vogl; C. Mueller; F. Triebel

doi:10.1016/j.annonc.2024.06.012

VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study

Robert Metcalf, S. Laban, C. A. Kristensen, T-E. Ciuleanu, I. Braña, A. Soria Rivas, S. M. Dieter, A. Bols, M. D. Forster, M. R. Covela, J. Christian, F. D. Vogl, C. Mueller, F. Triebel

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Meeting Abstract

Abstract

Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.

Original language	English
Journal	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume	35
Issue number	8
DOIs	https://doi.org/10.1016/j.annonc.2024.06.012
Publication status	Published - 11 Jul 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2024.06.012

Fingerprint

Dive into the research topics of 'VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study'. Together they form a unique fingerprint.

Cite this

Metcalf, R., Laban, S., Kristensen, C. A., Ciuleanu, T.-E., Braña, I., Soria Rivas, A., Dieter, S. M., Bols, A., Forster, M. D., Covela, M. R., Christian, J., Vogl, F. D., Mueller, C., & Triebel, F. (2024). VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 35(8). https://doi.org/10.1016/j.annonc.2024.06.012

Metcalf, Robert ; Laban, S. ; Kristensen, C. A. et al. / VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2024 ; Vol. 35, No. 8.

@article{9930dadb6d3742e0ae24758700be77cf,

title = "VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study",

abstract = "Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.",

author = "Robert Metcalf and S. Laban and Kristensen, {C. A.} and T-E. Ciuleanu and I. Bra{\~n}a and {Soria Rivas}, A. and Dieter, {S. M.} and A. Bols and Forster, {M. D.} and Covela, {M. R.} and J. Christian and Vogl, {F. D.} and C. Mueller and F. Triebel",

year = "2024",

month = jul,

day = "11",

doi = "10.1016/j.annonc.2024.06.012",

language = "English",

volume = "35",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

Metcalf, R, Laban, S, Kristensen, CA, Ciuleanu, T-E, Braña, I, Soria Rivas, A, Dieter, SM, Bols, A, Forster, MD, Covela, MR, Christian, J, Vogl, FD, Mueller, C & Triebel, F 2024, 'VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol. 35, no. 8. https://doi.org/10.1016/j.annonc.2024.06.012

VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. / Metcalf, Robert; Laban, S.; Kristensen, C. A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Vol. 35, No. 8, 11.07.2024.

Research output: Contribution to journal › Meeting Abstract

TY - JOUR

T1 - VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study

AU - Metcalf, Robert

AU - Laban, S.

AU - Kristensen, C. A.

AU - Ciuleanu, T-E.

AU - Braña, I.

AU - Soria Rivas, A.

AU - Dieter, S. M.

AU - Bols, A.

AU - Forster, M. D.

AU - Covela, M. R.

AU - Christian, J.

AU - Vogl, F. D.

AU - Mueller, C.

AU - Triebel, F.

PY - 2024/7/11

Y1 - 2024/7/11

N2 - Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.

AB - Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.

U2 - 10.1016/j.annonc.2024.06.012

DO - 10.1016/j.annonc.2024.06.012

M3 - Meeting Abstract

SN - 0923-7534

VL - 35

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 8

ER -

Metcalf R, Laban S, Kristensen CA, Ciuleanu TE, Braña I, Soria Rivas A et al. VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2024 Jul 11;35(8). doi: 10.1016/j.annonc.2024.06.012